Cancer Therapies Market in Europe by Type and Geography - Forecast and Analysis 2022-2026

Published: Mar 2022

Pages: 120

SKU: IRTNTR72658

Snapshot

The cancer therapies market share in Europe is expected to increase by USD 34.71 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.92%.

This cancer therapies market in Europe research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cancer therapies market in Europe segmentation by type (chemotherapy, targeted therapy, immunotherapy, and others) and geography (Germany, UK, France, Italy, and Rest of Europe). The cancer therapies market in Europe report also offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, and Pfizer Inc. among others.

What will the Cancer Therapies Market Size in Europe be During the Forecast Period?

Download the Free Report Sample to Unlock the Cancer Therapies Market Size in Europe for the Forecast Period and Other Important Statistics

Cancer Therapies Market in Europe: Key Drivers, Trends, and Challenges

The increased prevalence of cancer is notably driving the cancer therapies market growth in Europe, although factors such as the high cost of products may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cancer therapies market industry in Europe. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Cancer Therapies Market Driver in Europe

The increased prevalence of cancer is one of the key drivers supporting the cancer therapies market growth in Europe. The estimated national expenditure on cancer care in the UK in 2020 was around $8.51 billion. The diagnosis and treatment costs are likely to increase as the population ages, and more people are diagnosed with cancer. The costs of cancer treatment are also expected to increase as new and often more expensive treatments are adopted as standards of care.
To offer better treatment options for cancer, medical facilities such as hospitals need sensitive and reliable diagnostics for accurate and early cancer diagnosis. Molecular and companion diagnostics are popular methods for detecting different cancer types. The rise in the number of cancer cases will lead to increased demand for and use of cancer immunotherapy, prompting vendors to develop advanced and upgraded therapies further. These factors are driving the market growth.

Key Cancer Therapies Market Trend in Europe

The rise in R&D investment is one of the key trends supporting the cancer therapies market growth in Europe. There have been many advances in technology in the post-genomic era. These advances have led to the development of technologies such as deoxyribonucleic acid (DNA) sequencing, innovative biomarker discovery and drug delivery methods, in-situ hybridization, and others. These technologies help physicians detect and quantify specific DNA or ribonucleic acid (RNA) sequences and proteins for the early diagnosis and treatment of various hereditary diseases, including cancers, thereby improving clinical outcomes. The use of these technologies in the field of cancer has helped physicians obtain a better understanding of the pathogenesis of cancer. This has led to the development of specific devices for the diagnosis and treatment of cancer. Such developments are expected to boost the market growth during the forecast period.

Key Cancer Therapies Market Challenge in Europe

The high cost of products is one of the factors hindering the cancer therapies market growth in Europe. Most cancers are incurable and require individual-specific treatments. Therefore, several sequential or combination treatments are given to the individuals. This means physicians will try different methods if one drug or treatment fails, which, in turn, increases the cost burden for the patients. The high cost of drug development, right from the preclinical stage to approval, leads to the higher cost of the final cancer drugs. Furthermore, withdrawal or the inability of the drug to receive the necessary approvals can prove to be a huge cost burden for the manufacturers. In addition to the high price of cancer drugs, inadequate reimbursement policies lead to a lower adoption rate of cancer therapies in Europe. Such factors are negatively impacting the market growth.

This cancer therapies market in Europe analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the cancer therapies market in Europe as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cancer therapies market in Europe during the forecast period.

Who are the Major Cancer Therapies Market Vendors in Europe?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

This statistical study of the cancer therapies market in Europe encompasses successful business strategies deployed by the key vendors. The cancer therapies market in Europe is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

Bayer AG is a public company that is headquartered in Germany. It is a global company that generated a revenue of $50802 million and had around 99538 employees. Its revenue from the cancer therapies market in Europe contributes to its overall revenues, along with its other offerings, but is not a key revenue stream for the company.
Bayer AG - The company offers cancer therapies for prostrate, kidney and breast.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The cancer therapies market in Europe forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Cancer Therapies Market in Europe Value Chain Analysis

Our report provides extensive information on the value chain analysis for the cancer therapies market in Europe, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The value chain of the pharmaceuticals market includes the following core components:

Research and development (R&D) and drug discovery
Integration and product development
Manufacturing
Outbound logistics
Marketing and sales
Support activities
Innovation

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

Which are the Key Regions for Cancer Therapies Market n Europe?

For more insights on the market share of various regions Request for a FREE sample now!

34% of the market's growth will originate from Rest of Europe during the forecast period. Rest of Europe is the key market for cancer therapies market in Europe. Market growth in this region will be faster than the growth of the market in France and Italy.

Another key region offering significant growth opportunities to the vendors is Germany. The prevalence of cancer will facilitate the cancer therapies market growth in Germany over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the outbreak of COVID-19 had a negative impact on the market. However, as of early 2021, the number of COVID-19 cases reduced due to active COVID-19 vaccination drives. Thus, the cancer diagnostics which were previously halted have picked up their operation pace. With diagnostics being operational, this will lead to an increase in demand for cancer therapies in the region. Such factors will have a positive impact on the cancer therapies market growth during the forecast priod.

What are the Revenue-generating Type Segments in the Cancer Therapies Market In Europe?

To gain further insights on the market contribution of various segments Request for a FREE sample

The cancer therapies market share growth in Europe by the chemotherapy segment will be significant during the forecast period. Chemotherapy is the use of drugs to destroy cancer cells or to stop the growth of rapidly dividing cancer cells in the body. A chemotherapy regimen usually consists of a specific number of cycles that can be given over a set period. It is often given along with radiation therapy, called chemoradiation therapy, to increase the effectiveness of radiation therapy. Hence, the use of chemotherapy is expected to drive the growth of the segment during the forecast period

This report provides an accurate prediction of the contribution of all the segments to the growth of the cancer therapies market size in Europe and actionable market insights on post COVID-19 impact on each segment.

Cancer Therapies Market Scope in Europe
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 7.92%
Market growth 2022-2026	$ 34.71 billion
Market structure	Fragmented
YoY growth (%)	6.90
Regional analysis	Europe
Performing market contribution	Rest of Europe at 34%
Key consumer countries	Germany, UK, France, Italy, and Rest of Europe
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Novartis AG, and Pfizer Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Cancer Therapies Market in Europe Report?

CAGR of the market during the forecast period 2022-2026
Detailed information on factors that will drive cancer therapies market growth in Europe during the next five years
Precise estimation of the cancer therapies market size in Europe and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the cancer therapies industry in Europe across Germany, UK, France, Italy, and Rest of Europe
A thorough analysis of the market's competitive landscape and detailed information on vendors
Comprehensive details of factors that will challenge the growth of cancer therapies market vendors in Europe

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Table of Contents

***1. Executive Summary

**1.1 Market Overview

*Exhibit 01: Key Finding 1

*Exhibit 02: Key Finding 2

*Exhibit 03: Key Finding 5

*Exhibit 04: Key Finding 6

*Exhibit 05: Key Finding 7

*Exhibit 06: Key Finding 8

***2. Market Landscape

**2.1 Market ecosystem

*Exhibit 07: Parent market

*Exhibit 08: Market characteristics

**2.2 Value chain analysis

***3. Market Sizing

**3.1 Market definition

*Exhibit 09: Offerings of vendors included in the market definition

**3.2 Market segment analysis

*Exhibit 10: Market segments

**3.3 Market size 2021

**3.4 Market outlook: Forecast for 2021 - 2026

*3.4.1 Estimating growth rates for emerging and high-growth markets

*3.4.2 Estimating growth rates for mature markets

*Exhibit 11: Global - Market size and forecast 2021 - 2026 ($ billion)

*Exhibit 12: Global market: Year-over-year growth 2021 - 2026 (%)

***4. Five Forces Analysis

**4.1 Five Forces Summary

*Exhibit 13: Five forces analysis 2021 & 2026

**4.2 Bargaining power of buyers

*Exhibit 14: Bargaining power of buyers

**4.3 Bargaining power of suppliers

*Exhibit 15: Bargaining power of suppliers

**4.4 Threat of new entrants

*Exhibit 16: Threat of new entrants

**4.5 Threat of substitutes

*Exhibit 17: Threat of substitutes

**4.6 Threat of rivalry

*Exhibit 18: Threat of rivalry

**4.7 Market condition

*Exhibit 19: Market condition - Five forces 2021

***5.Market Segmentation by Type

**5.1 Market segments

*Exhibit 20: Type - Market share 2021-2026 (%)

**5.2 Comparison by Type

*Exhibit 21: Comparison by Type

**5.3 Chemotherapy - Market size and forecast 2021-2026

*Exhibit 22: Chemotherapy - Market size and forecast 2021-2026 ($ billion)

*Exhibit 23: Chemotherapy - Year-over-year growth 2021-2026 (%)

**5.4 Targeted therapy - Market size and forecast 2021-2026

*Exhibit 24: Targeted therapy - Market size and forecast 2021-2026 ($ billion)

*Exhibit 25: Targeted therapy - Year-over-year growth 2021-2026 (%)

**5.5 Immunotherapy - Market size and forecast 2021-2026

*Exhibit 26: Immunotherapy - Market size and forecast 2021-2026 ($ billion)

*Exhibit 27: Immunotherapy - Year-over-year growth 2021-2026 (%)

**5.6 Others - Market size and forecast 2021-2026

*Exhibit 28: Others - Market size and forecast 2021-2026 ($ billion)

*Exhibit 29: Others - Year-over-year growth 2021-2026 (%)

**5.7 Market opportunity by Type

*Exhibit 30: Market opportunity by Type

***6. Customer landscape

**6.1 Overview

*Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria

*Exhibit 31: ?Customer landscape?

***7. Geographic Landscape

**7.1 Geographic segmentation

*Exhibit 32: Market share by geography 2021-2026 (%)

**7.2 Geographic comparison

*Exhibit 33: Geographic comparison

**7.3 Germany - Market size and forecast 2021-2026

*Exhibit 34: Germany - Market size and forecast 2021-2026 ($ billion)

*Exhibit 35: Germany - Year-over-year growth 2021-2026 (%)

**7.4 UK - Market size and forecast 2021-2026

*Exhibit 36: UK - Market size and forecast 2021-2026 ($ billion)

*Exhibit 37: UK - Year-over-year growth 2021-2026 (%)

**7.5 France - Market size and forecast 2021-2026

*Exhibit 38: France - Market size and forecast 2021-2026 ($ billion)

*Exhibit 39: France - Year-over-year growth 2021-2026 (%)

**7.6 Italy - Market size and forecast 2021-2026

*Exhibit 40: Italy - Market size and forecast 2021-2026 ($ billion)

*Exhibit 41: Italy - Year-over-year growth 2021-2026 (%)

**7.7 Rest of Europe - Market size and forecast 2021-2026

*Exhibit 42: Rest of Europe - Market size and forecast 2021-2026 ($ billion)

*Exhibit 43: Rest of Europe - Year-over-year growth 2021-2026 (%)

**7.8 Key leading countries

*Exhibit 44: Key leading countries

**7.9 Market opportunity by geography

*Exhibit 45: Market opportunity by geography

***8. Drivers, Challenges, and Trends

**8.1 Market drivers

*8.1.1 Increased prevalence of cancer

*8.1.2 Introduction of combination therapies

*8.1.3 Increasing awareness about effective therapies in patient population

**8.2 Market challenges

*8.2.1 High cost of products

*8.2.2 Side effects associated with available medicines

*8.2.3 Lack of skilled professionals

*Exhibit 46: Impact of drivers and challenges

**8.3 Market trends

*8.3.1 Rise in R&D investment

*8.3.2 Advent of gene therapy

*8.3.3 Personalized therapeutics

***9. Vendor Landscape

**9.1 Overview

*Exhibit 47: Vendor landscape

*The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.

**9.2 Landscape disruption

*Exhibit 48: ?Landscape disruption?

*Exhibit 49: Industry risks

***10. Vendor Analysis

**10.1 Vendors covered

*Exhibit 50: Vendors covered

**10.2 Market positioning of vendors

*Exhibit 51: ?Market positioning of vendors?

*10.3 Amgen Inc.

*Exhibit 52: Amgen Inc. - Overview

*Exhibit 53: Amgen Inc. - Product and service

*Exhibit 54: Amgen Inc. - Key offerings

*Exhibit 55: Amgen Inc. - Key news

**10.4 AstraZeneca Plc

*Exhibit 56: AstraZeneca Plc - Overview

*Exhibit 57: AstraZeneca Plc - Product and service

*Exhibit 58: AstraZeneca Plc - Key offerings

**10.5 Bayer AG

*Exhibit 59: Bayer AG - Overview

*Exhibit 60: Bayer AG - Business segments

*Exhibit 61: Bayer AG - Key offerings

*Exhibit 62: Bayer AG - Segment focus

**10.6 Bristol Myers Squibb Co.

*Exhibit 63: Bristol Myers Squibb Co. - Overview

*Exhibit 64: Bristol Myers Squibb Co. - Product and service

*Exhibit 65: Bristol Myers Squibb Co. - Key offerings

*Exhibit 66: Bristol Myers Squibb Co. - Segment focus

**10.7 Eli Lilly and Co.

*Exhibit 67: Eli Lilly and Co. - Overview

*Exhibit 68: Eli Lilly and Co. - Business segments

*Exhibit 69: Eli Lilly and Co. - Key offerings

*Exhibit 70: Eli Lilly and Co. - Segment focus

*10.8 F. Hoffmann La Roche Ltd.

*Exhibit 71: F. Hoffmann La Roche Ltd. - Overview

*Exhibit 72: F. Hoffmann La Roche Ltd. - Business segments

*Exhibit 73: F. Hoffmann La Roche Ltd. - Key offerings

*Exhibit 74: F. Hoffmann La Roche Ltd. - Segment focus

**10.9 GlaxoSmithKline Plc

*Exhibit 75: GlaxoSmithKline Plc - Overview

*Exhibit 76: GlaxoSmithKline Plc - Product and service

*Exhibit 77: GlaxoSmithKline Plc - Key offerings

*Exhibit 78: GlaxoSmithKline Plc - Segment focus

**10.10 Merck and Co. Inc.

*Exhibit 79: Merck and Co. Inc. - Overview

*Exhibit 80: Merck and Co. Inc. - Business segments

*Exhibit 81: Merck and Co. Inc. - Key offerings

*Exhibit 82: Merck and Co. Inc. - Segment focus

**10.11 Novartis AG

*Exhibit 83: Novartis AG - Overview

*Exhibit 84: Novartis AG - Business segments

*Exhibit 85: Novartis AG - Key offerings

*Exhibit 86: Novartis AG - Segment focus

**10.12 Pfizer Inc.

*Exhibit 87: Pfizer Inc. - Overview

*Exhibit 88: Pfizer Inc. - Product and service

*Exhibit 89: Pfizer Inc. - Key offerings

***11. Appendix

**11.1 Scope of the report

*11.1.1 ????Market definition

*11.1.2 ????Objectives

*11.1.3 Notes and Caveats

**11.2 Currency conversion rates for US$

*Exhibit 90: ?Currency conversion rates for US$?

**11.3 Research Methodology

*Exhibit 91: ?Research Methodology

*Exhibit 92: ??Validation techniques employed for market sizing?

*Exhibit 93: ??Information sources

**11.4 List of abbreviations

*Exhibit 94: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

cancer therapies market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis